Back to results
US 11,028,443 B2Granted
Molecular methods for assessing urothelial disease
AssigneesShowa Denko Materials Co., Ltd., Showa Denko Materials (America), Inc., City of Sapporo
InventorsTaku Murakami, Cindy M. Yamamoto, Masato Mitsuhashi, Hiroshi Harada
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of collecting exosomes and microvesicles (EMV) from urine, isolating corresponding mRNA, and analyzing expression patterns in order to diagnose and treat various urothelial cancers. In particular, various expression patterns are analyzed through a unique diagnostic formula.
Claims19
A method for treating a urothelial cancer in a human subject comprising;
- identifying the subject for treating the urothelial cancer by identifying that an expression level of at least two markers selected from the group consisting of SLC2A1, S100A13, KRT17, GPRC5A, P4HA1, and HSD17B2 in urinary exosomes and microvesicles isolated from the subject is higher than an expression level of the at least two markers in a urine sample obtained from a non-urothelial cancer subject;
- and
- administering a treatment selected from the group consisting of cystoscopy, tumor resection, surgery, chemotherapy, and cystectomy to the subject.
A method for treating a human subject with a urothelial cancer, the method comprising:
- identifying the subject for treating the urothelial cancer by identifying an expression of at least two RNAs associated with said urothelial cancer, comparing said at least two RNAs in a vesicle isolated from a urine sample from said subject with an expression of said at least two RNAs in a vesicle isolated from a urine sample of a healthy human donor, wherein the at least two RNAs are selected from the group consisting of KRT17, SLC2A1, ALDOB, LINC00967, SLC16A9, CRH, PCAT4, AQP3, THAP7, FADS2, SERPINE1, AS1, OLFM3, S100A13, C5orf30, GINM1, GPRC5A, P4HA1, HSD17B2, and TOP1P1, wherein an increase in said expression of said at least two RNAs of said subject compared to said expression of said at least two RNAs of said donor indicates said subject has urothelial cancer when said increase is beyond a threshold level,
- wherein said comparing said expression of said at least two RNAs in said vesicle isolated from said urine sample further comprises:
- (a) capturing said vesicle from said sample from said subject by moving said sample from said subject across a vesicle-capturing filter,
- (b) loading a lysis buffer onto said vesicle-capturing filter, thereby lysing said vesicle to release a vesicle-associated RNA,
- (c) quantifying said expression of said at least two RNAs associated with urothelial cancer in said vesicle-associated RNA by PCR,
- administering a treatment selected from the group consisting of cystoscony, tumor resection, surgery, chemotherapy, and cystectomy to the subject having urothelial cancer.
3 more elements
Dependencies are inferred from the claim text.